Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Richardsen, Elin ^a,b   Uglehus, Rebecca Dale ^a   Johnsen, Stein Harald ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; KI 67 ANTIGEN; PTGS2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BREAST TUMOR; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL RATE; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RISK; SIGNAL TRANSDUCTION; STROMAL CELLS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84859191414     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-110     Document Type: Article

References (51)

1. Molecular themes in oncogenesis. Bishop JM, Cell 1991 64 235 248 10.1016/0092-8674(91)90636-D 1988146
2. Putting tumors in context. Bissel MJ, Radisky D, Nat Rev Cancer 2001 1 1 46 54 10.1038/35094059 11900251
3. Fibroblasts in cancer. Kalluri R, Zeisberg M, Nature 2006 6 5 392 401
4. The influence of extracellular matrix on gene expression: is struture the message? Bissel MJ, Barcellos-Hoff MH, J Cell Sci 1987 8 327 343 (Pubitemid 18041168)
5. Tumor-stromal interactions in breast cancer: the role of stroma in tumorigenesis. Kim JB, Stein R, Hare MJ, Tumor Biol 2005 26 4 173 185 10.1159/000086950 (Pubitemid 41379743)
6. Stroma in breast development and disease. Arent LM, Rudnick JA, Keller PJ, Kuperwasser C, Seminars in Cell & Development Biol 2010 21 11 18 10.1016/j.semcdb.2009.10.003 21854864
7. Crosstalk between cancer and immune cells: role of STAT3 in tumor microenvironment. Yu H, Kortylewski M, Pardoll D, Nature Rev Immunol 2007 7 1 41 51 10.1038/nri1995 (Pubitemid 46020826)
8. Mutations in the NK-B signaling pathway: implications for human disease. Courtois F, Gilmore RD, Oncogene 2006 25 51 6831 6843 10.1038/sj.onc.1209939 17072331 (Pubitemid 44657855)
9. NF-B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Niet V, Johnson RS, Haddad GG, Karin M, Nature 2008 5 453 807 811 (Pubitemid 351793778)
10. NK-B functions as a tumour promoter in inflammation-associated cancer. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Ureli-Shoval S, Galun E, Ben-Neriah Y, Nature 2004 431 7001 461 466 15329734 (Pubitemid 39329586)
11. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of Sp1/Sp3 transcription factors in human gliomas. Xu K, Shu HK, Cancer Res 2007 67 13 6121 6129 10.1158/0008-5472.CAN-07-0141 17616668 (Pubitemid 47037492)
12. TGF- and cancer. Bierie B, Moses HL, Cytokine Growth Factor Rev 2006 17 1-2 29 40 10.1016/j.cytogfr.2005.09.006 16289860 (Pubitemid 43117514)
13. Transforming growth factor-s and mammary gland involution; functional roles and implications for cancer progression. Flanders KC, Wakefield LM, J Mammary Gland Biol Neoplasia 2009 14 2 131 144 10.1007/s10911-009-9122-z 19396528
14. Clinical, cellular, and molecular aspects of cancer invasion. Marceel M, Leroy A, Physiol Rev 2003 83 2 337 376 12663862 (Pubitemid 36382891)
15. Transforming growth factor type ; rapid induction of fibrosis and angiogenesis in vivo and stimulating of collagen formation in vitro. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Proc Natl Acad Sci, USA 1986 83 12 4167 4171 10.1073/pnas.83.12.4167 2424019 (Pubitemid 16057012)
16. Expression of transforming growth factor-1 in prostate cancer. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER, Endocrinol 1994 35 5 2240 2247 (Pubitemid 24363924)
17. TGF- signalling is necessary for carcinoma cell invasiveness and metastases. Oft M, Heider KH, Beug H, Curr Biol 1998 8 23 1243 1252 10.1016/S0960-9822(07)00533-7 9822576 (Pubitemid 28540052)
18. TbetaR-1(6A) is a candidate tumor susceptibility allele. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzato L, Massagué J, Offit K, Cancer res 1999 59 22 5678 5682 10582683
19. Cytokines and immunoresponse in the tumor microenvironment. Mocellin S, Wang E, Marincola FM, J Immunother 2001 24 5 392 407 10.1097/00002371-200109000- 00002 11696695 (Pubitemid 33029909)
20. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Mantovani A, Sozzani S, Locate M, Allavena P, Sica A, Trends Immunol 2002 23 11 549 555 10.1016/S1471-4906(02)02302-5 12401408 (Pubitemid 35223554)
21. Cytokine polymorphisms, cancer susceptibility, and prognosis. Howell WM, Rose-Zerilli MJ, J Nutr 2007 137 1 suppl 194S 199S 17182825 (Pubitemid 46052880)
22. Regulation of tumor growth and metastases by interleucin-10: the melanoma experience. Huang S, Ullrich SE, Bar-Eli M, J Interferon Cytokine Res 1999 19 7 697 703 10.1089/107999099313532 10454339 (Pubitemid 29379811)
23. Interleukin-10 and the immune response against cancer: a counterpoint. Mocellin S, Marincola FM, Young HA, J Leucocyte Biol 2005 78 5 1043 1051 10.1189/jlb.0705358 (Pubitemid 41572467)
24. Relationship between IL-10 and tumormarkers in breast cancer. Llanes-Fernandez L, Alvarez-Goyanes RI, Arango-Prado Mdel C, Arango-Prado Mdel C, Alcocer-Gonzales JM, Mojarrieta JC, Perez XE, Lopez MO, Odio SF, Camacho-Rodriguez R, Guerra-Yi ME, Madrid-Mariana V, Tamez-guerra R, Rodriguez-Padilla C, The Breast 2006 15 4 482 489 10.1016/j.breast.2005.09.012 16403632 (Pubitemid 44159219)
25. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Köppel H, Waschner TC, Paulweber B, Samonigg H, Breast Cancer Res and Treat 2005 90 2 113 115 10.1007/s10549-004-3607-7 (Pubitemid 40568894)
26. Ki-67 as prognostic marker in early breast cancer: a met-analysis of published studies involving 12 555 patients. De Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Palesmans M, British J Cancer 2007 96 10 1504 1513 10.1038/sj.bjc.6603756 (Pubitemid 46762956)
27. It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment. Barcellos-Hoff MH, J Mammary Gland Biol Neoplasia 2001 6 2 213 221 10.1023/A:1011317009329 11501581 (Pubitemid 39600512)
28. The stroma as a Crucial target in rat mammary gland carcinogenesis. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C, J Cell Sci 2004 117 pt8 1495 1502 14996910 (Pubitemid 38559824)
29. Stromal effects on mammary gland development and Breast cancer. Wiseman BS, Werb Z, Science 2002 296 5570 1046 1049 10.1126/science.1067431 12004111 (Pubitemid 34517108)
30. Inflammatory cells and cancer: think different! Coussens LM, Werb Z, J Exp Med 2001 193 6 23 26 10.1084/jem.193.6.F23
31. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Schor S, Schor A, Breast Cancer Res 2001 3 6 373 379 10.1186/bcr325 11737888 (Pubitemid 34196363)
32. World Health Organizations; Tumors of the Breast and female Genital Organs. 2003 ISBN 92 832 24124
33. TMN-classification of Malignant Tumors. 6 UICC 2002, ISBN 0 471 222887
34. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD, Br J Cancer 1996 74 9 1445 1451 10.1038/bjc.1996.563 8912543 (Pubitemid 26370738)
35. Stromal fibroblasts in cancer initiation and progression. Bhowrmic NA, Neilson EG, Moses HL, Nature 2004 432 7015 332 337 10.1038/nature03096 15549095 (Pubitemid 39551661)
36. Novel multicellular organotypic models in normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression. Holliday DL, Brouilette KT, Markert A, Gordon LA, Jones JL, Breast Cancer Res 2009 11 1 3 10.1186/bcr2218 19152687
37. Cyclooxygenase-2 and prostaglandin signalling in cholangiocarcinoma. Wu T, Biochem and Biophys Acta 2005 1755 2 135 150
38. Molecular Prognostic factors in adenocarcinoma of esophagus and gastroesophageal junction. Lagarde SM, Kate FJW, Richel DJ, Offerhaus GJA, Lanschot JJB, Ann Surg Oncol 2006 24 26 4347 4355 (Pubitemid 46630794)
39. COX-2 and colon cancer: potential targets for chemoprevention. Fournier DB, Gordon GB, J Cell Biochem Suppl 2000 34 97 102 10762021 (Pubitemid 30176739)
40. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Gupta RA, Dubios RN, Nat Rev Cancer 2001 1 1 11 21 10.1038/35094017 11900248 (Pubitemid 33741877)
41. The role of Cyclooxygenase 2 expression in breast cancer. Singh-Ranger G, Salhab M, Mokbel K, Breast Ca Res Treat 2008 109 2 189 198 10.1007/s10549-007- 9641-5 (Pubitemid 351644840)
42. Relationship between expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Surowiak P, Maternal V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Breast Cancer Res 2005 7 5 862 879 10.1186/bcr1313
43. The role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K, Proc Natl Acad Sci 2009 106 9 3372 3377 3 10.1073/pnas.0813306106 19218449
44. A novel functional polymorphism in the transforming growth Factor beta2 gene promoter and tumor progression in breast cancer. Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, Zugmaier G, Pfizenmaier K, Knabbe C, Cancer Res 2006 66 15 7554 7561 1 10.1158/0008-5472.CAN-06-0634 16885354 (Pubitemid 44289211)
45. Elevated plasma transforming growth factor-1 levels in breast cancer patients decrease after surgical removal of tumor. Kong FM, Anscher MS, Murase T, Abbot BD, Iglehart JD, Jirtle RL, Ann Surgery 1995 222 22 155 162
46. Alteration in components of the TGF- superfamily signalling pathways in human cancer. Levy L, Hill CS, Cytokine Growth Factor Rev 2006 17 1-2 41 58 10.1016/j.cytogfr.2005.09.009 16310402 (Pubitemid 43117515)
47. TGF- signaling-related markers in cancer patients with bone metastasis. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Artega C, Carducci M, Biomarkers 2008 13 2 217 236 10.1080/13547500701676019 18270872 (Pubitemid 351250367)
48. TGF- signalling in tumor suppression and cancer progression. Derynck R, Akhurst RJ, Balmain A, Nat Genet 2001 29 2 117 129 10.1038/ng1001-117 11586292 (Pubitemid 32952643)
49. Ki-67 expression in operable breast cancer: A comparative study of immunostaining and real-time RT-PCR assay. Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Jesionek-Kupnica D, Pasz-Walczak G, Watala C, Kordek R, Pathology Res and Practice 2006 36 3 291 295
50. Image analysis and quantification in lung tissue. De Boer WI, Hiemstra PS, Sont JK, De Heer E, Rabe KF, Van Krieken JH, Sterk PJ, Clin and Exp Allergy 2001 31 3 504 508 10.1046/j.1365-2222.2001.01062.x (Pubitemid 34204173)
51. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Sullivan P, Stephens D, Ansari T, Costello J, Jeffrey P, Eur Respir 1998 12 4 811 815 10.1183/09031936.98. 12040811 (Pubitemid 28491649)